Effect of Baseline Serum Calcium on Responses to Extended-Release Calcifediol (ERC) in Stage 3 - 4 CKD

Nelson Kopyt DO, FASN, FACP
*Lehigh Valley Health Network, Nelson.Kopyt@lvhn.org*

Stephen A. Strugnell

Akhtar Ashfaq

Martin Petkovich

Charles W. Bishop

Follow this and additional works at: [http://scholarlyworks.lvhn.org/medicine](http://scholarlyworks.lvhn.org/medicine)

Part of the [Medical Sciences Commons](http://scholarlyworks.lvhn.org/medicine), and the [Nephrology Commons](http://scholarlyworks.lvhn.org/medicine)

Published In/Presented At


This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Effect of Baseline Serum Calcium on Responses to Extended-Release Calcifediol (ERC) in Stage 3-4 CKD

Nelson A. Kopyt1, Stephen A. Strugnell1, Akhtar Ashfaq2, Martin Petkovich3, Charles W. Bishop4

1Lehigh Valley Hospital, Bethlehem, PA; 2OPKO Health Renal Division, Miami, FL; 3Queens University, Kingston, ON, Canada

Table 1. Subject demographics at baseline

<table>
<thead>
<tr>
<th>Variable</th>
<th>Tertile 1</th>
<th>Tertile 2</th>
<th>Tertile 3</th>
<th>Mean (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
<td>11 (46)</td>
<td>10 (45)</td>
<td>11 (46)</td>
<td>32 (13)</td>
</tr>
<tr>
<td>Age, y</td>
<td>54.7 (0.8)</td>
<td>55.3 (0.8)</td>
<td>56.1 (0.8)</td>
<td>55.3 (0.8)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>32.4 (1.9)</td>
<td>32.7 (1.9)</td>
<td>32.0 (1.9)</td>
<td>32.4 (1.9)</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>119.0 (4.6)</td>
<td>119.9 (4.6)</td>
<td>118.5 (4.6)</td>
<td>119.3 (4.6)</td>
</tr>
<tr>
<td>Gender, %</td>
<td>4 (33)</td>
<td>4 (35)</td>
<td>3 (29)</td>
<td>13 (39)</td>
</tr>
<tr>
<td>Female</td>
<td>6 (55)</td>
<td>6 (60)</td>
<td>7 (64)</td>
<td>19 (56)</td>
</tr>
</tbody>
</table>

Figure 1. Changes in mean serum Ca

Figure 2. Changes in mean serum P

Figure 3. Changes in mean serum total 25D

Figure 4. Changes in mean plasma iPTH

Figure 5. Changes in mean plasma 25D

Conclusions

- ERC treatment effectively increased serum total 25D and 1,25D, and reduced mean plasma iPTH, in all tertiles.
- Baseline serum Ca affected serum 25D and plasma iPTH responses to ERC treatment.
- ERC-induced increases in 1,25D and decreases in iPTH were greater in subjects with the lowest baseline Ca.

References

1. Nakhla SM, Rosenthal AK, Kopyt NA, et al. Calcifediol (ERC) in mean serum total 25D and 1,25D, and on phosphorus (P), total Ca–P, plasma calcium (Ca), and on end measured with the Laboratory of Molecular Biology and Biotechnology, National Institutes of Health (2017) 11-11.
2. Nakhla SM, Rosenthal AK, Kopyt NA, et al. Calcifediol (ERC) in mean serum total 25D and 1,25D, and on phosphorus (P), total Ca–P, plasma calcium (Ca), and on end measured with the Laboratory of Molecular Biology and Biotechnology, National Institutes of Health (2017) 11-11.
3. Nakhla SM, Rosenthal AK, Kopyt NA, et al. Calcifediol (ERC) in mean serum total 25D and 1,25D, and on phosphorus (P), total Ca–P, plasma calcium (Ca), and on end measured with the Laboratory of Molecular Biology and Biotechnology, National Institutes of Health (2017) 11-11.

Acknowledgements

This study was sponsored by OPKO Health Renal Division.